ReviewBritish journal of pharmacology2018
Finding the needle in the haystack: systematic identification of psychobiotics.
Review in British journal of pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 103 citations in OpenAlex.
- Effects of the antibiotic rifaximin on cortical functional connectivity are mediated through insular cortex.Scientific reports · 2021Trial
- The Impact of Psychobiotic Therapy on Anxiety and Depressive Symptoms in Patients with Post-COVID Syndrome-A Randomized, Double-Blind, Placebo-Controlled Trial.Metabolites · 2026Article
- Nanocrystalline cellulose-geniposide complex enhances gut-brain axis modulation for depression treatment.Communications biology · 2025Article
- The microbiota-gut-brain axis in depression: unraveling the relationships and therapeutic opportunities.Frontiers in immunology · 2025Review
- The role of probiotics in modulation of the gut-brain axis: a prospective therapy for depression and mood disorders.Frontiers in pharmacology · 2025Review
- Nutritional Modulation of the Gut-Brain Axis: A Comprehensive Review of Dietary Interventions in Depression and Anxiety Management.Metabolites · 2024Review
- Article
- Hormetic Nutrition and Redox Regulation in Gut-Brain Axis Disorders.Antioxidants (Basel, Switzerland) · 2024Review
- metaProbiotics: a tool for mining probiotic from metagenomic binning data based on a language model.Briefings in bioinformatics · 2024Article
- Microbiota-Gut-Brain Axis and Antidepressant Treatment.Current topics in behavioral neurosciences · 2024Review
- The Gut-Brain Axis and the Microbiome in Anxiety Disorders, Post-Traumatic Stress Disorder and Obsessive-Compulsive Disorder.Current neuropharmacology · 2024Review
- Probiotics and Fecal Microbiota Transplantation in Major Depression: Doxa or Episteme?Advances in experimental medicine and biology · 2024Review
- Sodium butyrate ameliorates diabetic retinopathy in mice via the regulation of gut microbiota and related short-chain fatty acids.Journal of translational medicine · 2023Article
- The Neurobiology of Eating Behavior in Obesity: Mechanisms and Therapeutic Targets: A Report from the 23rd Annual Harvard Nutrition Obesity Symposium.The American journal of clinical nutrition · 2023Article
- Dysfunction of Inflammatory Pathways and Their Relationship with Anti-Hypothalamic Autoantibodies in Patients with Anorexia Nervosa.Nutrients · 2023Article
- A novel set of volatile urinary biomarkers for late-life major depressive and anxiety disorders upon the progression of frailty: a pilot study.Discover mental health · 2022Article
- Article
- Associations between self-reported psychological symptom severity and gut microbiota: further support for the microgenderome.BMC psychiatry · 2022Article
- Therapeutic Anti-Depressant Potential of Microbial GABA Produced byCurrent issues in molecular biology · 2022Review
- The effects of probiotics administration on the gut microbiome in adolescents with anorexia nervosa-A study protocol for a longitudinal, double-blind, randomized, placebo-controlled trial.European eating disorders review : the journal of the Eating Disorders Association · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The brain-gut-microbiota axis is increasingly viewed as a novel paradigm in neuroscience with the capacity to generate innovative therapies for patients with psychiatric illnesses. Psychobiotics, defined as live bacteria, which when ingested in adequate amounts, confer mental health benefits, are increasingly of interest, as preclinical trials continue to show promising results. Particularly in stress-related, anxiety and depressive disorders, there is potential for psychobiotics to deliver new therapies. The question of which microbes may prove to be the most promising psychobiotic in delivering such therapies at a clinical level is of great importance. Here we look at the characteristics of psychobiotics, in an attempt to present an outline from which the identification of potential new psychobiotics may be possible. LINKED ARTICLES: This article is part of a themed section on When Pharmacology Meets the Microbiome: New Targets for Therapeutics? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.24/issuetoc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.